About
Team
Pipeline
OPN-2853
OPN-6602
DEGRADERS
OPN-FMRP
OPN-7486
OPN-9840
OPN-9627
Patients
News
Press Releases
Publications
& Posters
Careers
Investors
Contact
General information
info@opnabio.com
Investor inquiries
bd@opnabio.com
Media and BD inquiries
bd@opnabio.com
2025
Select PROGRAMS
All Programs
Multi-Functional Degraders
(1)
OPN-2853
(10)
OPN-51107
(17)
OPN-6602
(3)
OPN-7486
(5)
OPN-TEAD
(2)
Select Dates
All Dates
2025
(3)
2024
(4)
2023
(3)
2022
(1)
2021
(3)
2020
(3)
2019
(7)
2018
(4)
2017
(3)
2016
(2)
2015
(3)
December 7, 2025
Poster
Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
AUTHORS
Mead et al
Programs
OPN-2853
Download PDF
December 7, 2025
Oral Presentation
Novel Multifunctional Degraders of EP300/CBP and IKZF1/3 with Potent Anti-Myeloma Activity
AUTHORS
Chen et al
Programs
Multi-Functional Degraders
Download PDF
November 5, 2025
Publication
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
AUTHORS
Ott, et al
Programs
OPN-TEAD
https://www.nature.com/articles/s41467-025-64682-7